Anagnostou Aikaterini, Greenhawt Matthew, Shaker Marcus, Vickery Brian P, Wang Julie
Department of Allergy and Immunology, Texas Children's Hospital, Houston, Texas.
Division of Allergy and Immunology, Children's Hospital Colorado, School of Medicine, University of Colorado, Aurora, Colorado.
Ann Allergy Asthma Immunol. 2025 Jan;134(1):110-121. doi: 10.1016/j.anai.2024.07.034. Epub 2024 Aug 24.
Food allergy management has greatly evolved in the last several years, moving from passive approaches, such as strict food allergen avoidance, to more active treatments, including regulatory approval of the first specifically indicated immunotherapy product (for peanut) in 2020. In 2024, a second therapy, omalizumab, received regulatory approval for the treatment of 1 or more IgE-mediated food allergies, providing clinicians with multiple treatment options to offer patients and families. With this expanded armamentarium of food allergy treatment options, the practicing clinician requires detailed knowledge of benefits and risks of omalizumab, how omalizumab fits into the management landscape, and how to use shared decision-making to optimize therapy. This yardstick aims to provide the clinician with a review of data leading to omalizumab's food allergy indication and an evidence-based expert opinion approach regarding on how best to use this and other therapies available to optimize patient management.
在过去几年中，食物过敏管理有了很大进展，从被动方法（如严格避免食物过敏原）转向更积极的治疗，包括2020年首个特异性指示免疫疗法产品（用于花生）获得监管批准。2024年，第二种疗法奥马珠单抗获得监管批准，用于治疗1种或更多种IgE介导的食物过敏，为临床医生提供了多种治疗选择，可供患者及其家属选择。随着食物过敏治疗选择的不断增加，执业临床医生需要详细了解奥马珠单抗的益处和风险、奥马珠单抗如何融入管理格局，以及如何使用共同决策来优化治疗。本准则旨在为临床医生提供对导致奥马珠单抗获得食物过敏适应症的数据的回顾，以及关于如何最好地使用该疗法和其他可用疗法以优化患者管理的循证专家意见方法。
